Latest General anesthetics Stories
REDWOOD CITY, Calif., May 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2013. "We continue to make progress in clinical development of our product candidates. We presented additional data at the recent American Society of...
- Reduces risks associated with oversedation, facilitates faster patient recovery and increases physician satisfaction - CINCINNATI, May 3, 2013 /PRNewswire/ -- Sedasys, a Division of Ethicon Endo-Surgery, Inc. (Ethicon), today announced that the U.S. Food and Drug Administration (FDA) has granted PMA approval for the SEDASYS(®) System, the first computer-assisted personalized sedation (CAPS) system. (Logo: http://photos.prnewswire.com/prnh/20130503/NY07585LOGO) The SEDASYS System...
CUPERTINO, Calif., May 2, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2013. Total revenues were $4.2 million and net loss was $5.2 million for the three months ended March 31, 2013. For comparison, total GAAP revenue was $41.2 million and net income was $30.8 million for the three months ended March 31, 2012. The revenue for the first quarter of 2012 included the accelerated recognition of $35.4 million in...
- Additional Phase 3 analysis show significantly faster reduction in pain and fewer patients with oxygen desaturation events for Sufentanil NanoTab PCA System than IV PCA with morphine - REDWOOD CITY, Calif., May 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional...
CUPERTINO, Calif., April 24, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 2, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...
- Patients in the 30 mcg sufentanil NanoTab treatment group experienced significantly greater reduction in pain as measured by SPID-12 vs. placebo - REDWOOD CITY, Calif., April 24, 2013 /PRNewswire/ --- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line results demonstrating that a placebo-controlled,...
Surgical patients who demonstrated heightened pain sensitivity, or hyperalgesia, induced by high doses of a synthetic opioid had their symptoms alleviated by co-treatment with dexmedetomidine, according to new research. Study investigators, who presented their results today at the 29th Annual Meeting of the American Academy of Pain Medicine, concluded that dexmedetomidine may be a new and effective treatment option for opioid-induced hyperalgesia (OIH). OIH refers to increased pain...
On February 25th, 2013, Hospira announced the recall of three lots of Propofol Injectable Emulsion due to visible particles embedded in the glass. In light of these news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Propofol side effects. http://www.attorneyone.com/propofol-recall/ San Diego, CA (PRWEB) March 27, 2013 AttorneyOne.com, a recognized authority on...
According to a new market report published by Transparency Market Research "Medical Gases and Equipment Market (Pure Gases, Gas Mixtures, Oxygen, Nitrous Oxide, Carbon Dioxide-Oxygen, Nitrous Oxide-Oxygen, Manifolds, Vacuum Systems)- Global Industry Analysis, Size, Share, Growth and Forecast, 2012 - 2018," in 2011, the global medical gases and equipment market was calculated at USD 5.3 billion and is expected to grow at a CAGR of 8% from 2012 to 2018, to reach an estimated value...
NEW YORK, March 20, 2013 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Medical Gases and Equipment Market (Pure Gases, Gas Mixtures, Oxygen, Nitrous Oxide, Carbon Dioxide-Oxygen, Nitrous Oxide-Oxygen, Manifolds, Vacuum Systems)- Global Industry Analysis, Size, Share, Growth and Forecast, 2012 - 2018," in 2011, the global medical gases and equipment market was calculated at USD 5.3 billion...
